secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azitra, Inc. (AZTR)
CIK:        0001701478
Form:       8-K
Filed at:   2026-02-27T23:59:59+00:00
Accession:  0001701478-26-000014
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azitra reports FY2025 net loss of $11.0M, cash $2.1M; pipeline advances
-----------------------------------------------------------------------

- Net loss widened to $11.0M in FY2025 from $9.0M in FY2024; R&D $4.8M, G&A $6.2M.
- Cash and equivalents of $2.1M as of Dec 31, 2025; completed $8.5M in financings during the year.
- First patient dosed in Phase 1/2 trial for ATR-04 (EGFRi rash); Fast Track from FDA.
- Topline data expected H2 2026 for ATR-12 (Netherton syndrome) and mid-2026 for ATR-04.
- Positive preclinical data for ATR-01 (ichthyosis vulgaris); IND-enabling studies continue in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701478/000170147826000014/0001701478-26-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701478/000170147826000014/aztr-20260227.htm
  HTML page:      https://secwatch.observer/filing/0001701478-26-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer